From 2018 through 2021, the FDA approved 1 in 10 drugs based on studies in which the drug candidates failed to meet their endpoints, the research found, according to USA Today. There were 210 new therapies approved during this time, and of those, 21 didn’t achieve at least one of their study’s main goals. Those approved drugs with unclear efficacy include Alzheimer’s, infectious disease, psychiatric and cancer treatments.
The FDA should ensure that its “rubber stamp … — considered the gold standard around the world — really means the drug has been proven to have safety and efficacy that outweighs any risk,” Reshma Ramachandran, MD, an assistant professor at Yale School of Medicine who co-authored the study, told USA Today.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
